Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Ivabradine and the SIGNIFY conundrum|
|Citation:||European Heart Journal, 2015; 36(46):3297-3299|
|Publisher:||Oxford University Press|
|John F. Beltrame|
|Abstract:||This editorial refers to ‘Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: the SIGNIFY study’, by K.M. Fox et al., on page doi:10.1093/eurheartj/XXX Stable angina is a prevalent and disabling condition that occurs in 10–14% of those aged 65–84 years,1 with population studies suggesting that almost a third of affected patients experience an angina episode at least once a week.2 Treatment focuses upon the alleviation of angina symptoms and the prevention of cardiac events. Although the development of cardioprotective agents has received considerable attention in recent years, there has been less progress with novel antianginal agents.|
|Keywords:||Humans; Heart Rate; Coronary Artery Disease|
|Rights:||© The Author 2015. For permissions please email: firstname.lastname@example.org|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.